Report Overview

North America Cancer Immunotherapy Market – Industry Trends & Forecast Report, 2030

North America Cancer Immunotherapy Market size by value was estimated at USD 24.61 billion in 2023. During the forecast period between 2024 and 2030, the North America Cancer Immunotherapy Market size is expected to expand at a CAGR of 11.15% reaching a value of USD 68.52 billion by 2030. North America Cancer Immunotherapy Market is primarily driven by the increasing incidence of cancer cases, rising demand for personalized medicine, advancements in biotechnology, and a growing understanding of immune checkpoints. Additionally, favorable government initiatives, extensive R&D activities, and collaborations among pharmaceutical companies contribute to market growth. Moreover, the introduction of novel immunotherapeutic agents, such as immune checkpoint inhibitors and chimeric antigen receptor (CAR) T-cell therapy, alongside expanding applications across various cancer types, further propel the market forward. Rapid adoption of immunotherapy as a standard treatment option, coupled with improving healthcare infrastructure, also fosters market expansion in North America.

Cancer Immunotherapy – Overview

Cancer immunotherapy harnesses the body's immune system to fight cancer cells. It includes various approaches, such as checkpoint inhibitors, CAR-T cell therapy, and cancer vaccines. Checkpoint inhibitors target molecules that prevent immune cells from attacking cancer, while CAR-T therapy modifies a patient's T cells to recognize and destroy cancer cells. Cancer vaccines stimulate the immune system to recognize and attack cancer-specific antigens. Immunotherapy offers promising results in treating various cancers, with fewer side effects compared to traditional treatments like chemotherapy and radiation therapy, marking a significant advancement in cancer treatment modalities.

North America Cancer Immunotherapy Market

Growth Drivers

Growing Adoption of Immunotherapy for Increasing Prevalence of Cancer

A key driver for the North American cancer immunotherapy market is the unfortunate rise in cancer diagnoses. With an aging population and increasing risk factors like smoking and obesity, the incidence of various cancers is expected to climb. This creates a larger patient pool seeking effective treatments, propelling the adoption of immunotherapy, which offers promising results with potentially fewer side effects compared to traditional therapies.

Challenges

High Cost and Reimbursement Challenges

Despite its advantages, a major restraint for the growth of North America market is the high cost of cancer immunotherapy drugs. These treatments can be financially burdensome for patients and healthcare systems. Additionally, complex reimbursement policies and lengthy approval processes by insurance companies can create access issues for patients, hindering wider market penetration.

Impact of Escalating Geopolitical Tensions on North America Cancer Immunotherapy Market

Escalating geopolitical tensions can significantly impact the North America Cancer Immunotherapy Market. Restrictions on trade, sanctions, or disruptions in supply chains due to geopolitical conflicts can hinder the availability of crucial immunotherapy drugs and technologies. Increased uncertainty may lead to fluctuations in investment and research funding, affecting the development of innovative therapies. Additionally, diplomatic tensions may impede international collaboration and hinder the exchange of scientific knowledge, potentially slowing down advancements in cancer immunotherapy. Further, geopolitical instability can affect healthcare infrastructure and access to treatment, particularly for vulnerable populations, thereby impacting the market's growth and adoption of immunotherapies. Overall, the North America Cancer Immunotherapy Market could face challenges in terms of research, development, accessibility, and investment amidst escalating geopolitical tensions.

North America Cancer Immunotherapy Market

Segmental Coverage

North America Cancer Immunotherapy Market – By Type of Therapy

Based on type of therapy, North America Cancer Immunotherapy Market is divided into Checkpoint Inhibitors, Monoclonal Antibodies, Vaccines, Cell Therapies, Immunomodulators, and Oncolytic Virus segments. The checkpoint inhibitors segment is the largest type of therapy in the North America Cancer Immunotherapy Market. These inhibitors, which include drugs like pembrolizumab and nivolumab, have garnered significant attention for their ability to enhance the body's immune response against cancer cells by blocking certain checkpoints that inhibit immune system activity. With extensive research and development efforts and proven efficacy in various cancer types, checkpoint inhibitors stand out as the leading segment, driving substantial market growth and adoption among healthcare providers and patients across North America.

North America Cancer Immunotherapy Market – By Distribution Channel

Based on distribution channel, North America Cancer Immunotherapy Market is divided into Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy segments. The hospital pharmacy segment typically represents the largest segment, owing to its accessibility, specialized oncology care, and availability of advanced immunotherapeutic treatments. Hospitals often serve as primary centers for cancer diagnosis, treatment, and management, thus witnessing higher demand for immunotherapy drugs. The segment's prominence underscores the crucial role hospitals play in cancer care delivery in the region, emphasizing the importance of healthcare infrastructure in facilitating effective cancer immunotherapy treatments.

North America Cancer Immunotherapy Market – By Application

Based on application, North America Cancer Immunotherapy Market is divided into Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, and Others (including Ovarian Cancer and Pancreatic Cancer) segments. The lung cancer segment holds the highest market share om the North America Cancer Immunotherapy Market. The segment often commands significant attention and investment due to the high prevalence of lung cancer cases in the region. Lung cancer is a leading cause of cancer-related mortality, driving substantial demand for innovative immunotherapeutic treatments.

North America Cancer Immunotherapy Market – By End User

Based on end user, North America Cancer Immunotherapy Market is divided into Hospitals & Clinics, and Cancer Research Centers segments. The hospitals & clinics segment represents the largest end user, accounting for a significant market share. These establishments serve as crucial centers for cancer treatment, offering a wide range of immunotherapy options to patients. With advanced medical facilities and expertise, hospitals and clinics play a pivotal role in administering immunotherapeutic interventions, contributing significantly to the growth and advancement of cancer immunotherapy in the North American region.

North America Cancer Immunotherapy Market – By Country

Based on country, North America Cancer Immunotherapy Market is divided into United States, and Canada. United States is the leading country, boasting a robust market driven by significant investments in research and development programs, a strong healthcare infrastructure, and a high prevalence of cancer cases. With a plethora of pharmaceutical companies engaged in immunotherapy research and development, coupled with favorable regulatory policies, the United States remains at the forefront of cancer immunotherapy advancements, accounting for the lion's share of the market in the region.

Competitive Landscape

Major players in the North America Cancer Immunotherapy Market include Pfizer Inc., AstraZeneca, Merck & Co., Inc., F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Novartis AG, Lilly, Johnson & Johnson Services, Inc., Bayer AG, Astellas Pharma Inc., Gilead Sciences, Inc., GSK plc, Sanofi, AbbVie Inc., and Atara Biotherapeutics, Inc. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

Scope of the Report

By Type of Therapy

• Checkpoint Inhibitors

• Monoclonal Antibodies

• Vaccines

• Cell Therapies

• Immunomodulators

• Oncolytic Virus

By Distribution Channel

• Hospital Pharmacy

• Retail Pharmacy

• Online Pharmacy

By Application

• Lung Cancer

• Breast Cancer

• Colorectal Cancer

• Melanoma

• Prostate Cancer

• Others (including Ovarian Cancer and Pancreatic Cancer)

By End User

• Hospitals & Clinics

• Cancer Research Centers

• Others

By Country

• United States

• Canada

1. Research Framework
   1. Research Objective
   2. Product Overview
   3. Market Segmentation
2. Executive Summary
3.  North America Cancer Immunotherapy Market Insights
   1. Industry Value Chain Analysis
   2. DROC Analysis
      1. Growth Drivers
         1. Rising cancer incidence
         2. Growing awareness and acceptance of immunotherapy
         3. Increasing government initiatives
      2. Restraints
         1. High cost of treatment
         2. Increasing safety concerns
         3. Complex regulatory landscape
      3. Opportunities
         1. Development of new and improved immunotherapy drugs
         2. Growing focus on personalized medicine
         3. Expansion into new indications
      4. Challenges
         1. Educating patients and healthcare providers
         2. Manufacturing challenges
   3. Technological Advancements/Recent Developments
   4. Regulatory Framework
   5. Porter’s Five Forces Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of New Entrants
      4. Threat of Substitutes
      5. Intensity of Rivalry
4. North America Cancer Immunotherapy Market: Marketing Strategies
5. North America Cancer Immunotherapy Market Overview
   1. Market Size & Forecast, 2019–2030
      1. By Value (USD Billion)
   2. Market Share and Forecast
      1. By Type of Therapy
         1. Checkpoint Inhibitors
         2. Monoclonal Antibodies
         3.  Vaccines
         4. Cell Therapies
         5.  Immunomodulators
         6. Oncolytic Virus
      2. By Distribution Channel
         1. Hospital Pharmacy
         2. Retail Pharmacy
         3. Online Pharmacy
      3. By Application
         1. Lung Cancer
         2. Breast Cancer
         3. Colorectal Cancer
         4. Melanoma
         5. Prostate Cancer
         6. Others (Ovarian Cancer, Pancreatic Cancer)
      4. By End User
         1. Hospitals & Clinics
         2. Cancer Research Centers
         3. Others
      5. By Country
         1. United States
         2. Canada
6. United States Cancer Immunotherapy Market
   1. Market Size & Forecast, 2019–2030
      1. By Value (USD Billion)
   2. Market Share & Forecast
      1. By Type of Therapy
      2. By Distribution Channel
      3. By Application
      4. By End User
7. Canada Cancer Immunotherapy Market
   1. Market Size & Forecast, 2019–2030
      1. By Value (USD Billion)
   2. Market Share & Forecast
      1. By Type of Therapy
      2. By Distribution Channel
      3. By Application
      4. By End User
8. Competitive Landscape
   1. List of Key Players and Their Offerings
   2. North America Cancer Immunotherapy Market Share Analysis, 2023
   3. Competitive Benchmarking, By Operating Parameters
   4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)
9. North America Cancer Immunotherapy Market: Import & Export
10. Impact of Geopolitical Tensions on North America Cancer Immunotherapy Market
11. Company Profiles (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, and SWOT Analysis)
    1. Pfizer Inc.
    2. AstraZeneca
    3. Merck & Co., Inc
    4. F. Hoffmann-La Roche Ltd
    5. Bristol-Myers Squibb Company
    6. Novartis AG
    7. Lilly
    8. Johnson & Johnson Services, Inc
    9. Bayer AG
    10. Astellas Pharma Inc.
    11. Gilead Sciences, Inc
    12. GSK plc
    13. Sanofi
    14. AbbVie Inc.
    15. Atara Biotherapeutics, Inc
    16. Other Prominent Players
12. Key Strategic Recommendations
13. Research Methodology
    1.    Qualitative Research
       1.  Primary & Secondary Research
    2.    Quantitative Research
    3.    Market Breakdown & Data Triangulation
       1.  Secondary Research
       2.  Primary Research
    4.    Breakdown of Primary Research Respondents, By Region
    5.    Assumptions & Limitations

*Financial information of case of non-listed companies can be provided as per availability.

**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable

List of Figures

Figure 1       North America Cancer Immunotherapy Segmentation

Figure 2       North America Cancer Immunotherapy Market Value Chain Analysis

Figure 3       Company Market Share Analysis, 2023

Figure 4       North America Cancer Immunotherapy Market Size, By Value (USD Billion), 2019–2030

Figure 5       North America Cancer Immunotherapy Market Share, By Type of Therapy, By Value (USD Billion), 2019–2030

Figure 6       North America Cancer Immunotherapy Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030

Figure 7       North America Cancer Immunotherapy Market Share, By Application, By Value (USD Billion), 2019–2030

Figure 8       North America Cancer Immunotherapy Market Share, By End User, By Value (USD Billion), 2019–2030

Figure 9       North America Cancer Immunotherapy Market Share, By Country, By Value (USD Billion), 2019–2030

Figure 10     United States Cancer Immunotherapy Market Size, By Value (USD Billion), 2019–2030

Figure 11     United States Cancer Immunotherapy Market Share, By Type of Therapy, By Value (USD Billion), 2019–2030

Figure 12     United States Cancer Immunotherapy Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030

Figure 13     United States Cancer Immunotherapy Market Share, By Application, By Value (USD Billion), 2019–2030

Figure 14     United States Cancer Immunotherapy Market Share, By End User, By Value (USD Billion), 2019–2030

Figure 15     Canada Cancer Immunotherapy Market Size, By Value (USD Billion), 2019–2030

Figure 16     Canada Cancer Immunotherapy Market Share, By Type of Therapy, By Value (USD Billion), 2019–2030

Figure 17     Canada Cancer Immunotherapy Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030

Figure 18     Canada Cancer Immunotherapy Market Share, By Application, By Value (USD Billion), 2019–2030

Figure 19     Canada Cancer Immunotherapy Market Share, By End User, By Value (USD Billion), 2019–2030

List of Tables

Table 1        North America Cancer Immunotherapy Market Size, By Value (USD Billion), 2019–2030

Table 2        North America Cancer Immunotherapy Market Share, By Type of Therapy, By Value (USD Billion), 2019–2030

Table 3        North America Cancer Immunotherapy Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030

Table 4        North America Cancer Immunotherapy Market Share, By Application, By Value (USD Billion), 2019–2030

Table 5        North America Cancer Immunotherapy Market Share, By End User, By Value (USD Billion), 2019–2030

Table 6        North America Cancer Immunotherapy Market Share, By Country, By Value (USD Billion), 2019–2030

Table 7        United States Cancer Immunotherapy Market Size, By Value (USD Billion), 2019–2030

Table 8        United States Cancer Immunotherapy Market Share, By Type of Therapy, By Value (USD Billion), 2019–2030

Table 9        United States Cancer Immunotherapy Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030

Table 10      United States Cancer Immunotherapy Market Share, By Application, By Value (USD Billion), 2019–2030

Table 11      United States Cancer Immunotherapy Market Share, By End User, By Value (USD Billion), 2019–2030

Table 12      Canada Cancer Immunotherapy Market Size, By Value (USD Billion), 2019–2030

Table 13      Canada Cancer Immunotherapy Market Share, By Type of Therapy, By Value (USD Billion), 2019–2030

Table 14      Canada Cancer Immunotherapy Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030

Table 15      Canada Cancer Immunotherapy Market Share, By Application, By Value (USD Billion), 2019–2030

Table 16      Canada Cancer Immunotherapy Market Share, By End User, By Value (USD Billion), 2019–2030

Table 17      Pfizer Inc. Company Overview                     

Table 18      Pfizer Inc. Financial Overview                      

Table 19      AstraZeneca Company Overview                            

Table 20      AstraZeneca Financial Overview                   

Table 21      Merck & Co., Inc Company Overview                     

Table 22      Merck & Co., Inc Financial Overview                      

Table 23      F. Hoffmann-La Roche Ltd Company Overview                           

Table 24      F. Hoffmann-La Roche Ltd Financial Overview                  

Table 25      Bristol-Myers Squibb Company: Company Overview                  

Table 26      Bristol-Myers Squibb Company Financial Overview                     

Table 27      Novartis AG Company Overview                   

Table 28      Novartis AG Financial Overview                    

Table 29      Lilly Company Overview                     

Table 30      Lilly Financial Overview                      

Table 31      Johnson & Johnson Services, Inc Company Overview                          

Table 32      Johnson & Johnson Services, Inc Financial Overview                           

Table 33      Bayer AG Company Overview                      

Table 34      Bayer AG Financial Overview                       

Table 35      Astellas Pharma Inc. Company Overview                         

Table 36      Astellas Pharma Inc. Financial Overview                          

Table 37      Gilead Sciences, Inc Company Overview                          

Table 38      Gilead Sciences, Inc Financial Overview                           

Table 39      GSK plc Company Overview                         

Table 40      GSK plc Financial Overview                          

Table 41      Sanofi Company Overview                           

Table 42      Sanofi Financial Overview                  

Table 43      AbbVie Inc. Company Overview                   

Table 44      AbbVie Inc. Financial Overview                    

Table 45      Atara Biotherapeutics, Inc Company Overview                           

Table 46      Atara Biotherapeutics, Inc Financial Overview